HP
PYXS icon

HealthInvest Partners’s Pyxis Oncology PYXS Stock Holding History

HealthInvest Partners’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.91M Buy
966,459
+769,423
+390% +$1.47M 0.78% 37
2026
Q1 		$1.62M Sell
197,036
-420,209
-68% -$633K 0.52% 39
2025
Q4 		$710K Buy
+617,245
New +$2.18M 0.23% 39

Other funds holding PYXS

Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
HIMS
Hager Investment Management Services New London, New Hampshire $217M AUM 56.89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
FUBT
First United Bank & Trust Oakland, Maryland $348M AUM 25.01% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

HealthInvest Partners's PYXS Position: Q2 2026 in Review

HealthInvest Partners increased its Pyxis Oncology (PYXS) stake by 390% in Q2 2026, buying an estimated $1.47M and bringing the position to 966,459 shares worth $2.91M. The position accounts for 0.78% of the portfolio, ranked #37.

HealthInvest Partners first reported a position in PYXS in Q4 2025 and has held it in 3 quarters since. 8 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • HealthInvest Partners held 966,459 shares of Pyxis Oncology worth $2.91M as of Q2 2026.
  • HealthInvest Partners bought 769,423 Pyxis Oncology shares in Q2 2026, an estimated $1.47M.
  • Pyxis Oncology made up 0.78% of HealthInvest Partners's portfolio in Q2 2026, its #37 holding.
  • HealthInvest Partners first reported a position in Pyxis Oncology in Q4 2025 and has held it in 3 quarters since.
  • 8 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.